(Q37803416)

23 August 2017

title

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis (English)

1 reference

juvenile rheumatoid arthritis

23 August 2017

0 references

1 reference

1 reference

4

Nico M Wulffraat

1 reference

23 August 2017

Joost Frans Swart

1

1 reference

23 August 2017

Daantje Barug

series ordinal

2

1 reference

23 August 2017

Michelle Möhlmann

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

28 October 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1743-1752

1 reference

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Adult outcomes of patients with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Burden and cost of illness in patients with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

The German etanercept registry for treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Early effects of Anakinra in corticosteroid naïve SOJIA patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

A case of macrophage activation syndrome successfully treated with anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Defining off-label and unlicensed use of medicines for children: results of a Delphi survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Unlicensed and off label drug use by children in the community: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.532785

10.1517/14712598.2010.532785

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference